Therapy for fgfr1 rearrangement-associated cancer
By using compound of formula I to contact cancers carrying BCR-FGFR1, ZNF198-FGFR1 and/or FOP-FGFR1 fusion genes, FGFR1 rearrangement in these cancers was inhibited, achieving effective treatment and prevention of EMS and SCLL.
CN122892686APending Publication Date: 2026-10-09GUANGZHOU SHUNJIAN PHARM CO LTD +2
2 Cites 0 Cited by
Patent Information
- Application Number
- CN202580010530.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-01-19
- Filing Date
- 2025-01-17
- Publication Date
- 2026-10-09
AI Technical Summary
Technical Problem
Existing treatment options for FGFR1 rearrangement-related cancers, particularly hematologic cancers such as 8p11 myeloproliferative syndrome (EMS) or stem cell leukemia/lymphoma syndrome (SCLL), are limited and have poor prognoses.
Method used
Compounds of Formula I and their pharmaceutically acceptable salts are provided for contact with cancers carrying BCR-FGFR1, ZNF198-FGFR1, and/or FOP-FGFR1 fusion genes, to achieve therapeutic or preventative effects by inhibiting the activity of these fusion proteins.
Benefits of technology
Compound A significantly inhibited apoptosis in FGFR1 rearrangement-related cancers, reduced the number of tumor cells, suppressed tumor growth, and improved patient survival.
✦ Generated by Eureka AI based on patent content.
Abstract
The present disclosure relates to the use of compounds of Formula I, wherein the variables are as defined in the specification, and methods of using the same, for treating or preventing FGFR1 rearrangement-associated cancers. I
Need to check novelty before this filing date? Find Prior Art